

INNOVATION

Why this solution/product is innovative, the broad implications for future research, and/or how it will improve the human condition

Mymee closes the gap in care for patients who have uncontrolled disease flares and inadequate response to treatments. While FDA approved autoimmune Rx and following nutrition and health guidelines help countless patients to sustain remission and minimize symptoms, others are left highly vulnerable to their exposome (food, medication, supplements, excipients, toxins, climate, stresses, pathogens, vaccines). For these patients, trial & error between drugs, diets and alternative health interventions can increase risk of exposure to hidden triggers and drug-supplement-food interactions.

Participating in a personalized trial & care program capable of identifying direct correlations between negative triggers, positive health interventions and symptoms severity, helps patients gain control of their disease flares and work with their doctor to reduce or optimize their drug regimen if needed. [Testimonials from patients credit Mymee with giving them their life back](#), no longer being afraid of their body, being able to laugh again, going back to work, and canceling surgeries.

Mymee Inc is a pioneer in personalized trials & care for patients with uncontrolled autoimmune and long COVID disease flares. Mymee's proprietary personalized trial & care platform is clinically validated and SOC-II and HIPAA-compliant. In peer-reviewed studies, Mymee delivered statistically significant improvements in all ten HRQoL PROMIS® domains and a >40% mean reduction in 59 patient-reported symptoms. Peer-reviewed publications include Rheumatic & Musculoskeletal Disease Open Journal ('23), IFM Conf ('23 & '20), ACR Conf ('22), JMIR Lupus (SLE) Publication ('20) and IEEE conf ('20). Mymee has received industry recognition including Top 100 NY Healthcare Startups 2022 & 2023, Health 2.0 Outstanding Leadership Award: CEO & Founder 2022, Juniper Networks Awards 2022: #1 Most Innovative Precision Medicine Solution, Nominee Prix Galien Award: Digital Health, 2021, Honoree Fast Company World Changing Ideas Awards 2021.

Real world studies show personalized trial research & care delivers measurable value to providers and payers as well as patients. Non-responders to autoimmune biologics who still struggle with uncontrolled flares at the end of Step Therapy is one of the highest human & economic cost problems to solve.

Key findings demonstrate that Mymee's personalized trial & care platform enables:

- Statistically significant improvements in all 10 HRQoL PROMIS® domains and >40% mean reduction in 59 patient-reported symptoms; the more severe, the greater the improvement ^{1, 2 (corp 2 pager)}
- [>30% reduction in polypharmacy, addressing a key risk factor in rheumatic diseases.](#)
- 98% improvement in patients' perceived ability to work with their doctor to manage symptoms.
- Average \$11k Rx savings per autoimmune biologic and targeted therapy non-responder per year, as audited by a commercial insurer (based on list prices (WAC) prior to rebates).